Journals / Göztepe Tıp Dergisi / 2014 / Cilt: 29 - Sayı: 2

Methotrexate and its clinical usages in dermatology

Metotreksat ve dermatolojide klinik kullanımları

Pages
104–110
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the light of relevant information clinical usages of methotrexate in dermatological diseases were presented with recent literature data hoping to use this drug as a promising remedy of many untreated diseases in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Methotrexate is an immunsuppressive drug for use in inflammatory diseases by dermatologists, and used successfully for over 40 years for a wide variety of cutaneous diseases.
📊
Key Findings & Data:In addition to its antiproliferative properties due to being a folic acid analog, methotrexate has other more recently recognized anti-inflammatory properties related to its effects on adenosine.
💡
Conclusion & Impact:In the light of relevant information clinical usages of methotrexate in dermatological diseases were presented with recent literature data hoping to use this drug as a promising remedy of many untreated diseases in the future.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Methotrexate is an immunsuppressive drug for use in inflammatory diseases by dermatologists, and used successfully for over 40 years for a wide variety of cutaneous diseases. In addition to its antiproliferative properties due to being a folic acid analog, methotrexate has other more recently recognized anti-inflammatory properties related to its effects on adenosine. In this review pharmacokinetics, mode of administration, dosing guidelines, side effect profile, and medication interactions of methotrexate were evaluated, and important points to be considered during monitorization were reviewed. In the light of relevant information clinical usages of methotrexate in dermatological diseases were presented with recent literature data hoping to use this drug as a promising remedy of many untreated diseases in the future.

Özet

Metotreksat dermatolojide yaklaşık 40 yıldır birçok inflamatuvar hastalıkta başarıyla kullanılan bir immunsupresif ilaçtır. Folik asid analoğu olarak anti proliferatif etkisi yanında adenosin üzerine etkileriyle anti-inflamatuvar özelliktedir. Bu makalede, metotreksatın farmokinetiği, etki mekanizması, dozaj ve tedavi şemaları eşliğinde değerlendirilerek yan etki profili ile birlikte, izlemde dikkat edeceğimiz hususlar gözden geçirilmiştir. Bu bilgiler ışığında metoreksatın dermatolojik hastalıklardaki klinik kullanımı gelecekte tedavi edilmemiş hastalıklarda umut olması dileğiyle son literatür tabanlı verilerle geniş olarak sunulmuştur

🔖

Cite This Article

ÖZLÜ, E., KAVALA, M., TÜRKOĞLU, Z. (2022). Methotrexate and its clinical usages in dermatology. Göztepe Tıp Dergisi, Cilt: 29 - Sayı: 2, 104–110. https://ajindex.com/articles/524529

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007;(4):216-28.
  2. Roenigk HHJr, Auerbach R, Malbach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85. http://dx.doi.org/10.1016/S0190-9622(98)70508-0
  3. Dutz JP, Ho VC. Immunosuppresive agents in dermatology: an update. Dermatol Clinic 1998;16(2):235-50.
  4. Kalb RE, Strober B, Weinstein G, Lebwahl H. Methotrexa- te and psoriasis. 2009 National Psoriasis Foundation Con- sensus Conference. J Am Acad Dermatol 2009;60:824-37. http://dx.doi.org/10.1016/j.jaad.2008.11.906
  5. Lindsay K, Fraser AD, Layton A et al. Liver fibrosis in pa- tients with psoriasis and psoriatic arthritis on long term, high cumulative dose methotrexate therapy. Rheumatology 2009;48(5):569-72. http://dx.doi.org/10.1093/rheumatology/kep023
  6. Nast A, Boehncke WH, Mrowietz U et al. Guidelines on the teratment of psoriasis vulgaris (English version) update. J Dtsch Dermatol Ges 2012;10:51-99. http://dx.doi.org/10.1111/j.1610-0387.2012.07919.x
  7. Berends MA, Snoek J, de Jong EM et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther 2006;24(5):805-11. http://dx.doi.org/10.1111/j.1365-2036.2006.03047.x
  8. Thomas JA, Aithal GP. Monitoring liver function during methotrexate therapy for psoriasis:are routine biopsies re- ally necessary? Am J Clin Dermatol 2005;6(6):357-63. http://dx.doi.org/10.2165/00128071-200506060-00003
  9. Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol 1996;21(6):399-408. http://dx.doi.org/10.1111/j.1365-2230.1996.tb00142.x
  10. Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology 2007;46(10):1520-4. http://dx.doi.org/10.1093/rheumatology/kem147
  11. Milojevic M, Citotoksiena V, Kardaglı C. Dermatologia Beograd: Vojnoizdavacki Zavod. 2000; 2251-6.
  12. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years, experience with low dose long term treatment. J Eur Acad Dermatol Venereol 2000;14:382-8. http://dx.doi.org/10.1046/j.1468-3083.2000.00058.x
  13. Van Dooren-Greebe RJ, Kuljpers AL, Mulder J et al. Met- hotrexate revisited: effects of long term treatment in psori- asis. Br J Dermatol 1994;130:204-10. http://dx.doi.org/10.1111/j.1365-2133.1994.tb02901.x
  14. Collin B, Ogboli M, Moss C. Methotrexate therapy in 10 children with severe plaque psoriasis. Clin Exp Dermatol 2009;34(3):295-8. http://dx.doi.org/10.1111/j.1365-2230.2008.02907.x
  15. Juangin G, Zhigiand C, Zicla H. Evaluation of the effecti- venes